The raised guidance and strong double-digit growth in both segments signal sustained momentum. Watch for Q4 execution on the new oxygenator line and the 2028 CPT code catalyst for sleep apnea therapy.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 4 $94.19entry
- T+1 · 12d ago −3.24%α +1.17% · $91.14
- T+5 · 6d ago −3.41%α −2.50% · $90.98
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
LivaNova reported Q3 2026 revenue of $393.1M (+9.9% YoY reported, +10.0% constant-currency), above the $381.1M consensus. Adjusted diluted EPS of $1.23 beat the $1.06 consensus. The company raised full-year 2026 revenue growth guidance to 9%-10% constant-currency (from 8%-9%) and adjusted EPS guidance to $4.40-$4.50 (from $4.30-$4.40). GAAP EPS was $0.11, depressed by a $34.0M other operating expense (3T Heater-Cooler litigation provision).
Key Financial Metrics
Key Facts
- Q3 2026 revenue $393.1M, +9.9% reported, +10.0% constant-currency YoY
- Adjusted diluted EPS $1.23 vs $1.06 consensus (beat by 16.0%)
- GAAP diluted EPS $0.11, impacted by $34.0M other operating expense (3T litigation provision)
- Full-year 2026 revenue growth guidance raised to 9%-10% constant-currency (from 8%-9%)
- Full-year 2026 adjusted EPS guidance raised to $4.40-$4.50 (from $4.30-$4.40)
- Cardiopulmonary revenue $225.3M (+10.9% reported, +10.9% constant-currency)
- Neuromodulation revenue $166.1M (+11.1% reported, +11.2% constant-currency)
- Adjusted operating income $92.3M vs $80.4M in prior year
- Q3 operating cash flow $73.7M, adjusted free cash flow $55.8M
- Operational launch of new oxygenator manufacturing line
- AMA established new Category I CPT codes for proximal hypoglossal nerve stimulation therapy (effective Jan 1, 2028)
Financial Impact
Revenue beat consensus by $12.0M (3.1%); adjusted EPS beat by $0.17 (16.0%); guidance raised by 100bps on revenue and $0.10 at midpoint on EPS
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Cardiopulmonary | $225.3M | +10.9% |
| Neuromodulation | $166.1M | +11.1% |
Risk Factors
- 3T Heater-Cooler litigation provision ($34.0M in Q3) remains an ongoing expense and liability
- Other revenue declined 65.7% YoY due to a prior-year reserve reversal not repeating
- GAAP operating margin compressed to 7.2% from 15.1% due to litigation charges
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001639691-26-000111 |
| Document: livn-20261104.htm | 0001639691-26-000111 |
| Document: 0001639691-26-000111-index-headers.html | 0001639691-26-000111 |
| Document: 0001639691-26-000111-index.html | 0001639691-26-000111 |
| Document: 0001639691-26-000111.txt | 0001639691-26-000111 |
| 8-K Data (Synthetic) | 0001639691-26-000111 |
Track record
10 reports on LIVN
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +20.95% at T+60 after the May 6, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $91.32 Now $92.44 +1.23% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $90.98 Now $92.44 +1.60% settles Feb 9
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $91.14 Now $92.44 +1.43% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 6/10 Viewing Entry $94.19 Now $92.44 −1.86% settles Feb 2
- Sep 14, 20269w ago Insider Cluster Neutral 2/10 Entry $79.47 Now $92.44 +16.32% settles Dec 9
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $78.93 Now $92.44 +17.12% settles Dec 3
- Aug 5, 202614w ago 8-K Bullish 7/10 Entry $78.15 to $81.52 Now $92.44 +18.29% ▲ +4.32% +4.13% vs SPY
- May 6, 202627w ago 8-K Bullish 8/10 Entry $66.26 to $80.14 Now $92.44 +39.51% ▲ +20.95% +18.89% vs SPY
- Apr 29, 202628w ago DEFA14A Neutral 2/10 Entry $58.92 to $78.19 Now $92.44 +56.89% ▲ +32.71% +28.59% vs SPY
- Feb 25, 202637w ago 8-K Bullish 7/10 Entry $70.29 to $73.71 Now $92.44 +31.51% ▲ +4.87% −2.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers